Gilead's Hepatitis C Drug Works Against All Strains in Trial

  • New drug combination wiped out virus in 99% of patients
  • Gilead says it will file for drug approval by year-end

An experimental hepatitis C drug combination from Gilead Sciences Inc. wiped out multiple strains of the virus in a large clinical trial, giving the company an advantage against AbbVie Inc. in the race to treat as many patients as possible.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.